Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Nico Chen from DBS maintained a Buy rating on the stock and has a $130.00 price target.
Nico Chen has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong market position and growth potential. The company is a global leader in the interventional medical device sector, with a historical revenue growth rate of 9.8%, surpassing the industry average. This growth is largely driven by its electrophysiology segment, particularly with products like FARAPULSE for atrial fibrillation treatment.
Boston Scientific is also expanding its product portfolio through strategic mergers and acquisitions, which strengthens its foothold in cardiovascular and neurosurgery markets. Additionally, the company faces low tariff risks due to its manufacturing locations, which are primarily outside of high-risk tariff regions. Although there is competition from Chinese manufacturers offering similar products at lower prices, Boston Scientific maintains a premium pricing strategy due to its superior clinical outcomes. These factors contribute to the Buy rating with a target price of USD 130.
In another report released on March 20, RBC Capital also maintained a Buy rating on the stock with a $116.00 price target.
Based on the recent corporate insider activity of 134 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.